Antibody Drug Conjugates (ADC) Market To Hit USD 29.10 Billion By 2032, Driven By Rising Cancer Cases
Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...
Roche Emerging From Difficult Covid Comparisons With Solid Pharma and Diagnostics Prospects
We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...
appliedclinicaltrialsonline26d
Long-Term KATHERINE Trial Analysis Shows Kadcyla Significantly Improves Survival in HER2-Positive Early Breast Cancer
An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab emtansine) significantly improves overall survival and long-term invasive ...
pharmaphorum6y
Roche seeks Kadcyla boost to fend off Herceptin biosimilars
Kadcyla (trastuzumab emtansine) is already approved for people with metastatic HER2-positive breast cancer after treatment with Herceptin (trastuzumab) and chemotherapy.